Introduced
by
To impose a new mandate on manufacturers of prescription drugs that they must file detailed reports with a state agency on the costs associated with developing and marketing very expensive prescription drugs with prices that have risen by 25 percent or more in the past five years.
Referred to the Committee on Government Operations
